You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesoxycorticosterone Pivalate
Accession NumberDB01134  (APRD00709)
TypeSmall Molecule
GroupsExperimental, Vet Approved
DescriptionDesoxycorticosterone Pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air. It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methanol, ether and vegetable oils. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
Structure
Thumb
Synonyms
11-deoxycorticosterone pivalate
Deoxycorticosterone Pivalate
Deoxycorticosterone Trimethylacetate
Deoxycortolone Pivalate
Deoxycortone Pivalate
Deoxycortone Trimethylacetate
Desoxycorticosterone Trimethylacetate
Desoxycortone Pivalate
DOCP
DTMA
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Cortexone MNot Available
Neodin-DepositumNot Available
PercortenNot Available
Percorten MNot Available
Percorten PivalateNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII16665T4A2X
CAS number808-48-0
WeightAverage: 414.586
Monoisotopic: 414.277009704
Chemical FormulaC26H38O4
InChI KeyVVOIQBFMTVCINR-WWMZEODYSA-N
InChI
InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1
IUPAC Name
2-[(1S,2R,10S,11S,14S,15S)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl]-2-oxoethyl 2,2-dimethylpropanoate
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)COC(=O)C(C)(C)C
Pharmacology
IndicationExamined for treatment of adrenocortical insufficiency especially in multiple sclerosis, congenital cerebral palsy, polyarteritis nodosa, and rheumatoid arthritis. Currently only approved in treating cats and dogs for the treatment of Addison's disease.
Structured Indications Not Available
PharmacodynamicsUsed to treat adrenocortical insufficiency, desoxycorticosterone pivalate is a mineralocorticoid hormone and an analogue of desoxycorticosterone. It primarily acts on the metabolism of sodium, potassium and water. When the drug is given, there is decreased excretion of sodium accompanied by increased excretion of potassium; the concentration of sodium in the blood is thereby increased whereas that of potassium is decreased. There is a concomitant increase in the volume of blood and extracellular fluids, with a fall in hematocrit. It increases the rate of renal tubular absorption of sodium.
Mechanism of actionDesoxycorticosterone Pivalate binds to the mineralocorticoid receptor. Mineralocorticoids are a family of steroids, secreted by the adrenal cortex, necessary for the regulation of a number of metabolic processes including electrolyte regulation. Desoxycorticosterone pivalate exerts its effect through its interaction with the mineralocorticoid receptor (MR), whereby it reacts with the receptor proteins to form a steroid-receptor complex. This complex moves into the nucleus, where it binds to chromatin which results in genetic transcription of cellular DNA to messenger RNA. The steroid hormones appear to induce transcription and synthesis of specific proteins, which produce the physiological effects seen after administration.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mineralocorticoid receptorProteinyes
agonist
HumanP08235 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding90%
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desoxycorticosterone Pivalate.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Desoxycorticosterone Pivalate.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Desoxycorticosterone Pivalate.Approved
AldesleukinDesoxycorticosterone Pivalate may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desoxycorticosterone Pivalate.Approved
AmiodaroneThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BDesoxycorticosterone Pivalate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desoxycorticosterone Pivalate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desoxycorticosterone Pivalate.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Desoxycorticosterone Pivalate.Approved, Investigational
AprepitantThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desoxycorticosterone Pivalate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desoxycorticosterone Pivalate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desoxycorticosterone Pivalate.Approved, Investigational
BazedoxifeneThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desoxycorticosterone Pivalate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Desoxycorticosterone Pivalate.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Desoxycorticosterone Pivalate.Investigational
Bismuth SubcitrateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desoxycorticosterone Pivalate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desoxycorticosterone Pivalate.Investigational
BumetanideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desoxycorticosterone Pivalate.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desoxycorticosterone Pivalate.Experimental
CDX-110The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desoxycorticosterone Pivalate.Approved, Investigational
CeritinibDesoxycorticosterone Pivalate may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved
ChlorothiazideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneDesoxycorticosterone Pivalate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Desoxycorticosterone Pivalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Desoxycorticosterone Pivalate.Approved
CobicistatThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Desoxycorticosterone Pivalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Desoxycorticosterone Pivalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Desoxycorticosterone Pivalate.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Desoxycorticosterone Pivalate.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Desoxycorticosterone Pivalate.Investigational
DarunavirThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Desoxycorticosterone Pivalate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved
DienestrolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoxycorticosterone Pivalate.Approved
DihydrotestosteroneDesoxycorticosterone Pivalate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Desoxycorticosterone Pivalate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desoxycorticosterone Pivalate.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Desoxycorticosterone Pivalate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Desoxycorticosterone Pivalate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Desoxycorticosterone Pivalate.Approved
EstradiolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Estrone.Approved
Etacrynic acidDesoxycorticosterone Pivalate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Desoxycorticosterone Pivalate.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Desoxycorticosterone Pivalate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desoxycorticosterone Pivalate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoxycorticosterone Pivalate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desoxycorticosterone Pivalate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Desoxycorticosterone Pivalate.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desoxycorticosterone Pivalate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desoxycorticosterone Pivalate.Approved
FenthionThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Desoxycorticosterone Pivalate.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Desoxycorticosterone Pivalate.Vet Approved
FluoxymesteroneDesoxycorticosterone Pivalate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desoxycorticosterone Pivalate.Approved, Investigational
FosaprepitantThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Fosphenytoin.Approved
FurosemideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Desoxycorticosterone Pivalate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Desoxycorticosterone Pivalate.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Desoxycorticosterone Pivalate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoxycorticosterone Pivalate.Approved, Investigational
HydrochlorothiazideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desoxycorticosterone Pivalate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Desoxycorticosterone Pivalate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Desoxycorticosterone Pivalate.Approved
IdelalisibThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Desoxycorticosterone Pivalate.Approved
IndapamideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desoxycorticosterone Pivalate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desoxycorticosterone Pivalate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Desoxycorticosterone Pivalate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desoxycorticosterone Pivalate.Withdrawn
ItraconazoleThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desoxycorticosterone Pivalate.Experimental
KetoconazoleThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desoxycorticosterone Pivalate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Desoxycorticosterone Pivalate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desoxycorticosterone Pivalate.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoxycorticosterone Pivalate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desoxycorticosterone Pivalate.Approved
LumacaftorThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desoxycorticosterone Pivalate.Approved, Investigational
MagaldrateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoxycorticosterone Pivalate.Approved
Magnesium TrisilicateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desoxycorticosterone Pivalate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desoxycorticosterone Pivalate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desoxycorticosterone Pivalate.Approved
MestranolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Desoxycorticosterone Pivalate.Withdrawn
MethallenestrilThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneDesoxycorticosterone Pivalate may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneDesoxycorticosterone Pivalate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Desoxycorticosterone Pivalate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Minaprine.Approved
MitotaneThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoxycorticosterone Pivalate.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desoxycorticosterone Pivalate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoxycorticosterone Pivalate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desoxycorticosterone Pivalate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desoxycorticosterone Pivalate.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Desoxycorticosterone Pivalate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Desoxycorticosterone Pivalate.Investigational
NefazodoneThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desoxycorticosterone Pivalate.Approved
NevirapineThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desoxycorticosterone Pivalate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desoxycorticosterone Pivalate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desoxycorticosterone Pivalate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoxycorticosterone Pivalate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desoxycorticosterone Pivalate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Desoxycorticosterone Pivalate.Vet Approved
OxandroloneDesoxycorticosterone Pivalate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoxycorticosterone Pivalate.Approved
OxymetholoneDesoxycorticosterone Pivalate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoxycorticosterone Pivalate.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desoxycorticosterone Pivalate.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Desoxycorticosterone Pivalate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved
PhenytoinThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desoxycorticosterone Pivalate.Approved, Investigational
PiretanideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desoxycorticosterone Pivalate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoxycorticosterone Pivalate.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desoxycorticosterone Pivalate.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Desoxycorticosterone Pivalate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Quinestrol.Approved
QuinethazoneDesoxycorticosterone Pivalate may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone Pivalate.Experimental, Investigational
RifabutinThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Desoxycorticosterone Pivalate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Rosoxacin.Approved
S EquolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desoxycorticosterone Pivalate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desoxycorticosterone Pivalate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desoxycorticosterone Pivalate.Approved
SaquinavirThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desoxycorticosterone Pivalate.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Desoxycorticosterone Pivalate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Desoxycorticosterone Pivalate.Investigational
St. John's WortThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololDesoxycorticosterone Pivalate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desoxycorticosterone Pivalate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Desoxycorticosterone Pivalate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Desoxycorticosterone Pivalate.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Desoxycorticosterone Pivalate.Approved
TelithromycinThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desoxycorticosterone Pivalate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Desoxycorticosterone Pivalate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desoxycorticosterone Pivalate.Approved
TestosteroneDesoxycorticosterone Pivalate may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desoxycorticosterone Pivalate.Approved
TiboloneThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desoxycorticosterone Pivalate.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desoxycorticosterone Pivalate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desoxycorticosterone Pivalate.Approved
TorasemideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Desoxycorticosterone Pivalate.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Trichlorfon.Vet Approved
TrichlormethiazideDesoxycorticosterone Pivalate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desoxycorticosterone Pivalate.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desoxycorticosterone Pivalate.Investigational, Withdrawn
VoriconazoleThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinDesoxycorticosterone Pivalate may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoxycorticosterone Pivalate.Approved
ZeranolThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Desoxycorticosterone Pivalate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desoxycorticosterone Pivalate.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (65.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9553
Caco-2 permeable+0.6211
P-glycoprotein substrateSubstrate0.6541
P-glycoprotein inhibitor IInhibitor0.9048
P-glycoprotein inhibitor IIInhibitor0.8603
Renal organic cation transporterNon-inhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8702
CYP450 2D6 substrateNon-substrate0.9101
CYP450 3A4 substrateSubstrate0.8098
CYP450 1A2 substrateNon-inhibitor0.9498
CYP450 2C9 inhibitorNon-inhibitor0.8229
CYP450 2D6 inhibitorNon-inhibitor0.9356
CYP450 2C19 inhibitorNon-inhibitor0.8875
CYP450 3A4 inhibitorNon-inhibitor0.8554
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7501
Ames testNon AMES toxic0.9473
CarcinogenicityNon-carcinogens0.9159
BiodegradationNot ready biodegradable0.9231
Rat acute toxicity1.7883 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9494
hERG inhibition (predictor II)Non-inhibitor0.7297
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00141 mg/mLALOGPS
logP3.9ALOGPS
logP5.57ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)17.19ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area60.44 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity117.26 m3·mol-1ChemAxon
Polarizability48.3 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • 3-oxo-delta-4-steroid
  • 3-oxosteroid
  • Oxosteroid
  • Delta-4-steroid
  • Cyclohexenone
  • Alpha-acyloxy ketone
  • Carboxylic acid ester
  • Cyclic ketone
  • Ketone
  • Carboxylic acid derivative
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Carbonyl group
  • Organooxygen compound
  • Organic oxide
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Beaumont K, Fanestil DD: Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. [PubMed:6227474 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Sekihara H, Island DP, Liddle GW: New mineralocorticoids: 5alpha-dihydroaldosterone and 5alpha-dihydro-11-deoxycorticosterone. Endocrinology. 1978 Oct;103(4):1450-2. [PubMed:744157 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23